WEBULL
WebtradeDownload

Incyte (INCY) Could Be 12% Below Fair Value On ESMO Oncology Data Focus

Simply Wall St · 2d ago

Incyte (INCY) is drawing attention after announcing plans to showcase new oncology data at the European Society of Medical Oncology Congress 2026 in Madrid, starting October 23.

Despite the pullback in the past month, with a 30 day share price return down 9%, interest around Incyte’s ESMO data comes after a year where the share price return is up 11.85% year to date and the 1 year total shareholder return is 28.82%. This hints that longer term momentum has been materially stronger than the recent dip.

Look beyond Incyte and this ESMO catalyst by reviewing oncology-focused stocks with strong financial profiles in our curated list of solid balance sheet and fundamentals (25 results)

Bulls point to Incyte’s long track record of marketed drugs and oncology pipeline, while bears highlight recent revenue and net income declines. Which side does the current valuation favor as the stock pulls back from recent gains?

Most Popular Narrative: 12% Undervalued

Incyte’s most followed valuation narrative places fair value at $128.48 per share, above the last close of $113.44. This frames the current pullback as a discount to that view.

The main thing that has to go right is successful execution across the emerging franchises in mutation-directed MPNs, GI oncology, dermatology and hematology, including delivery of pivotal trial programs and integration of acquired assets like latarcibart.

The current valuation and this narrative’s bearish, fairly valued stance imply that the share price already reflects both the planned non-Jakafi growth and the risks around higher spending, GI oncology uncertainty and pipeline gaps such as the discontinued JAK2 V617F program.

See why 57 investors see Incyte as 12% undervalued.

Result: Fair Value of $128.48 (UNDERVALUED)

Still, setbacks in key GI oncology or MPN trials, or weaker than expected uptake of non Jakafi therapies, could quickly erode that 12% undervaluation narrative.

Find out about the key risks to this Incyte narrative.

Next Steps

If this mix of optimism and concern around Incyte feels familiar, move quickly to inspect the numbers, weigh the risks, and assess the upside using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Incyte?

Do not stop with one oncology story when the broader market still offers fresh angles, different risk levels, and income profiles that could better match your plan.